Publication:
Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 Cepheus Trial

Simple item page
dc.authorwosidLiu, Weiping/T-7052-2017
dc.authorwosidUsmani, Saad/Hci-4676-2022
dc.authorwosidMaiolino, Angelo/Aak-1471-2021
dc.authorwosidBraunstein, Marc/Jwp-8833-2024
dc.authorwosidGrosicki, Sebastian/Aag-2917-2019
dc.authorwosidBeksac, Meral/D-6411-2013
dc.contributor.authorUsmani, Saad Z.
dc.contributor.authorFacon, Thierry
dc.contributor.authorHungria, Vania
dc.contributor.authorBahlis, Nizar J.
dc.contributor.authorVenner, Christopher P.
dc.contributor.authorBraunstein, Marc
dc.contributor.authorZweegman, Sonja
dc.contributor.authorIDBasu, Supratik/0000-0003-2206-4796
dc.contributor.authorIDBahlis, Nizar/0000-0001-7353-7034
dc.contributor.authorIDUsmani, Saad/0000-0002-5484-8731
dc.date.accessioned2025-12-11T01:30:43Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Usmani, Saad Z.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Facon, Thierry] Univ Lille, Serv Malad Sang, CHU Lille, Lille, France; [Hungria, Vania] Clin Med Sao Germano, Sao Paulo, Brazil; [Bahlis, Nizar J.] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada; [Venner, Christopher P.] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada; [Venner, Christopher P.] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada; [Braunstein, Marc] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA; [Pour, Ludek] Univ Hosp Brno, Brno, Czech Republic; [Marti, Josep M.] Hosp Univ Mutua Terrassa, Terrassa, Spain; [Basu, Supratik] Royal Wolverhampton NHS Trust, Wolverhampton, England; [Basu, Supratik] Univ Wolverhampton, Natl Inst Hlth & Care Res, CRN West Midlands, Wolverhampton, England; [Cohen, Yael C.] Tel Aviv Sourasky Ichilov Med Ctr, Dept Hematol, Tel Aviv, Israel; [Cohen, Yael C.] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv, Israel; [Matsumoto, Morio] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Japan; [Suzuki, Kenshi] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan; [Hulin, Cyrille] Univ Hosp, Hop Haut Leveque, Dept Hematol, Pessac, France; [Grosicki, Sebastian] Med Univ Silesia, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland; [Legiec, Wojciech] St John Dukla Oncol Ctr Lublin Land, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland; [Beksac, Meral] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye; [Maiolino, Angelo] Inst Amer Ensino Pesquisa & Inovacao, Rio de Janeiro, Brazil; [Maiolino, Angelo] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil; [Perrot, Aurore] Univ Toulouse, Serv Hematol, CHU Toulouse, IUCT O, Toulouse, France; [Turgut, Mehmet] Ondokuz Mayis Univ, Fac Med, Fac Med, Samsun, Turkiye; [Ahmadi, Tahamtan] Genmab US Inc, Plainsboro, NJ USA; [Liu, Weiping] Johnson &Johnson, Shanghai, Peoples R China; [Wang, Jianping; Krevvata, Maria; Carey, Jodi; Carson, Robin] Johnson & Johnson PRD, Spring House, PA 19477 USA; [Chastain, Katherine; Lopez-Masi, Lorena] Johnson & Johnson, Raritan, NJ USA; [Vermeulen, Jessica] Johnson & Johnson, Beerse, Belgium; [Rowe, Melissa] Johnson & Johnson, High Wycombe, England; [Zweegman, Sonja] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlandsen_US
dc.descriptionBasu, Supratik/0000-0003-2206-4796; Bahlis, Nizar/0000-0001-7353-7034; Usmani, Saad/0000-0002-5484-8731en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1038/s41591-025-03581-2
dc.identifier.endpage1366en_US
dc.identifier.issn1078-8956
dc.identifier.issn1546-170X
dc.identifier.issue4en_US
dc.identifier.pmid39948407
dc.identifier.scopusqualityQ1
dc.identifier.startpage1366en_US
dc.identifier.urihttps://doi.org/10.1038/s41591-025-03581-2
dc.identifier.urihttps://hdl.handle.net/20.500.12712/44188
dc.identifier.volume31en_US
dc.identifier.wosWOS:001421474700001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofNature Medicineen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleDaratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 Cepheus Trialen_US
dc.typeCorrectionen_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu